Spectrum Pharmaceuticals

Drugs

Approved drugs

• Fusilev for injection is a drug that was approved by the U.S. Food and Drug Administration in 2008 for the US; the drug had been on the market in a number of European countries.
• Folotyn is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma.
• Khapzory , for injection, a folate analog for three indications:
• *Rescue after high-dose methotrexate therapy in patients with osteosarcoma.
• *Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination.
• *The treatment of patients with metastatic colorectal cancer in combination with fluorouracil.
• Zevalin is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma, including patients with rituximab-refractory follicular NHL. It is a CD-20 radio-antibody.
• Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It was approved by the FDA in 2012.
• Beleodaq is an HDAC inhibitor for relapsed or refractory peripheral T-cell lymphoma.
• Evomela is an alkalyating drug for multiple myeloma.

  In development

• Qapzola is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan invested money in 2008 to help develop this medication further and bring it to the market.
• Rolontis is in phase III trials for treatment of chemotherapy-induced neutropenia.
• Poziotinib is a quinazoline-based pan-HER inhibitor that blocks signaling through HER tyrosine-kinase receptors including HER1, HER2, and HER4. It is currently in phase II trials.